Loss of BAP1 expression has also been identified in several other tumour types including uveal melanoma (47%) (Harbour et al., 2010), clear cell renal carcinoma (CCRC) (14%) (Peña-Llopis et al., 2012) and cholangiocarcinoma (7%) (Fujimoto et al., 2015). Here, BAP1 is linked to cholangiocarcinoma.